Fair enough JJ, it could well go a bit lower. I will be a buyer here and lower. Unlike my spec stocks where its make or break on the entry price, DLS will perform over the long term (IMHO).
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor